Rs776746
From SNPedia
| is a | snp |
| is | mentioned by |
| dbSNP | rs776746 |
| hapmap | rs776746 |
| hgdp | rs776746 |
| ensembl | rs776746 |
| gopubmed | rs776746 |
| scholar | rs776746 |
| rs776746 | |
| pharmgkb | rs776746 |
| hgvbaseg2p | rs776746 |
| medrefsnp | rs776746 |
| 23andMe | rs776746 |
| SNP Nexus |
| Gene | CYP3A5 |
| Chromosome | 7 |
| Orientation | minus |
| Position | 99108474 |
| Genotype | Effect |
|---|---|
| rs776746(A;A) | nonfunctional CYP3A5; drug metabolism effects |
| rs776746(A;G) | carrier of 1 nonfunctional CYP3A5 allele; drug metabolism affects |
| rs776746(G;G) |
| Genotypes | Magnitude | Summary |
|---|---|---|
| Rs776746(A;A) | 33 | nonfunctional CYP3A5; drug metabolism effects |
| Rs776746(A;G) | 22 | carrier of 1 nonfunctional CYP3A5 allele; drug metabolism affects |
| Rs776746(G;G) | 00 |
rs776746, also known as 6986G>A, is a SNP encoding the (nonfunctional) CYP3A5*3 allele of the CYP3A5 gene.
CYP3A5*3 has been studied especially in connection with the metabolism of tacrolimus, an immunosuppressive drug used in organ transplantation. The optimal therapeutic dose is in a relatively narrow window, so blood concentration monitoring is recommended. CYP3A5*3 carriers tend to build up higher levels of tacrolimus than CYP3A5*1 carriers, unless their tacrolimus intake is reduced.
| ? | (A;A) (A;G) (G;G) |
|---|---|
|
| |
| PharmGKB | PA161145175 |
| Name | CYP3A5*3, CYP3A5:6986A>G |
| Annotation | Nonfunctional variant of CYP3A5. |
| Gene | CYP3A5, CYP3A |
| Featue | Intron, NA |
| Evidence | Web Resource:http://www.pharmgkb.org/search/annotatedGene/cyp3a5/variant.jsp#ImportantVariantInformationforCYP3A5-3 |
| Drugs | |
| Diseases | |
| Curation Level | In-Depth |
